R01NIH · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESNIH

Immunologic and Clinical Sequelae after COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases

Sparks, Jeffrey Andrew (Contact)·BRIGHAM AND WOMEN'S HOSPITAL, MA·2023–2028·ACTIVE

Donate

INSTITUTION

BRIGHAM AND WOMEN'S HOSPITAL, MA

PRINCIPAL INVESTIGATOR

Sparks, Jeffrey Andrew (Contact)

FUNDING

$706K

YEAR

2023

MOONBASE SCORE

Still being scored

LOADING MOONBASE SCORE

Abstract

PROJECT SUMMARY The 5 million Americans living with systemic autoimmune rheumatic diseases (SARDs), such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), are at increased risk of poor COVID-19 outcomes. SARO treatment with immunomodulators may lead to blunted and dysregulated immune responses to vaccination and infection. SARDs are characterized by a predisposition to autoantibody formation and fibrosis. These factors may place SARDs at risk for poor short-term outcomes (e.g., breakthrough infection, prolonged viral shedding) and post-acute sequelae of COVID-19 (PASC), characterized by prolonged COVID-19 symptoms (>/=28 days). PASC is of high clinical and

R01Neurological, Aging and Musculoskeletal Epidemiology Study Section[NAME]NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESresponsesautoimmuneclinicalplaceinfectionsystemicviralbreakthroughsequelaebluntedsymptomsamericanslupussardstreatmentcharacterizedmillionpredisposition

Are you the primary organization running this research?

The two tools below are built for the principal investigator & host institution behind this project.